181 related articles for article (PubMed ID: 38213329)
21. Intracranial implantation with subsequent 3D in vivo bioluminescent imaging of murine gliomas.
Abdelwahab MG; Sankar T; Preul MC; Scheck AC
J Vis Exp; 2011 Nov; (57):e3403. PubMed ID: 22158303
[TBL] [Abstract][Full Text] [Related]
22. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
23. Interferon-gamma-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas.
Svane IM; Engel AM; Nielsen M; Werdelin O
Scand J Immunol; 1997 Oct; 46(4):379-87. PubMed ID: 9350289
[TBL] [Abstract][Full Text] [Related]
24. Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes.
Letchuman V; Ampie L; Shah AH; Brown DA; Heiss JD; Chittiboina P
Neurosurg Focus; 2022 Feb; 52(2):E5. PubMed ID: 35104794
[TBL] [Abstract][Full Text] [Related]
25. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of radiation fractionation regimens on glioblastoma.
McKelvey KJ; Hudson AL; Donaghy H; Stoner SP; Wheeler HR; Diakos CI; Howell VM
Radiat Oncol; 2022 Jan; 17(1):17. PubMed ID: 35073960
[TBL] [Abstract][Full Text] [Related]
27. Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta(12,14)-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway.
Seo SK; Seo DI; Park WS; Jung WK; Lee DS; Park SG; Choi JS; Kang MS; Choi YH; Choi I; Yu BC; Choi IW
Life Sci; 2014 Sep; 112(1-2):82-9. PubMed ID: 25072357
[TBL] [Abstract][Full Text] [Related]
28. Rescue of MHC-1 antigen processing machinery by down-regulation in expression of IGF-1 in human glioblastoma cells.
Pan Y; Trojan J; Guo Y; Anthony DD
PLoS One; 2013; 8(3):e58428. PubMed ID: 23526983
[TBL] [Abstract][Full Text] [Related]
29. An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation.
Fu Y; Tian G; Li J; Zhang Z; Xu K
Int J Mol Med; 2020 Oct; 46(4):1501-1513. PubMed ID: 32700748
[TBL] [Abstract][Full Text] [Related]
30. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
[TBL] [Abstract][Full Text] [Related]
31. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract][Full Text] [Related]
32. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
33. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
34. Glucose fluxes in glycolytic and oxidative pathways detected in vivo by deuterium magnetic resonance spectroscopy reflect proliferation in mouse glioblastoma.
Simões RV; Henriques RN; Cardoso BM; Fernandes FF; Carvalho T; Shemesh N
Neuroimage Clin; 2022; 33():102932. PubMed ID: 35026626
[TBL] [Abstract][Full Text] [Related]
35. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Zaretsky JM; Garcia-Diaz A; Shin DS; Escuin-Ordinas H; Hugo W; Hu-Lieskovan S; Torrejon DY; Abril-Rodriguez G; Sandoval S; Barthly L; Saco J; Homet Moreno B; Mezzadra R; Chmielowski B; Ruchalski K; Shintaku IP; Sanchez PJ; Puig-Saus C; Cherry G; Seja E; Kong X; Pang J; Berent-Maoz B; Comin-Anduix B; Graeber TG; Tumeh PC; Schumacher TN; Lo RS; Ribas A
N Engl J Med; 2016 Sep; 375(9):819-29. PubMed ID: 27433843
[TBL] [Abstract][Full Text] [Related]
36. Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease.
Chen CH; Chin RL; Hartley GP; Lea ST; Engel BJ; Hsieh CE; Prasad R; Roszik J; Shingu T; Lizee GA; Heimberger AB; Millward SW; Hu J; Hong DS; Curran MA
Neuro Oncol; 2023 Aug; 25(8):1415-1427. PubMed ID: 36705543
[TBL] [Abstract][Full Text] [Related]
37. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
[TBL] [Abstract][Full Text] [Related]
38. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
[TBL] [Abstract][Full Text] [Related]
39. Tumor evolution selectively inactivates the core microRNA machinery for immune evasion.
Song TY; Long M; Zhao HX; Zou MW; Fan HJ; Liu Y; Geng CL; Song MF; Liu YF; Chen JY; Yang YL; Zhou WR; Huang DW; Peng B; Peng ZG; Cang Y
Nat Commun; 2021 Dec; 12(1):7003. PubMed ID: 34853298
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of defective antigen processing in human prostate cancer.
Sanda MG; Restifo NP; Walsh JC; Kawakami Y; Nelson WG; Pardoll DM; Simons JW
J Natl Cancer Inst; 1995 Feb; 87(4):280-5. PubMed ID: 7707419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
